Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery

Research output: Contribution to journalJournal articleResearchpeer-review

  1. IL-6 release from muscles during exercise is stimulated by lactate-dependent protease activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glucose and Amino Acid Metabolism in Mice Depend Mutually on Glucagon and Insulin Receptor Signaling

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Paracrine Crosstalk between Intestinal L- and D-cells Controls Secretion of Glucagon-Like Peptide-1 in mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impaired lipolysis in propionic acidemia: A new metabolic myopathy?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of protein intake prior to carbohydrate-restricted endurance exercise: a randomized crossover trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. High-fat overfeeding impairs peripheral glucose metabolism and muscle microvascular eNOS Ser1177 phosphorylation

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Christoffer Martinussen
  • Simon Veedfald
  • Carsten Dirksen
  • Kirstine N Bojsen-Møller
  • Maria S Svane
  • Nicolai J Wewer Albrechtsen
  • Gerrit van Hall
  • Viggo B Kristiansen
  • Mogens Fenger
  • Jens J Holst
  • Sten Madsbad
View graph of relations

Enhanced meal-related enteroendocrine secretion, particularly of glucagon-like peptide-1 (GLP-1), contributes to weight-loss and improved glycemia after Roux-en-Y gastric bypass (RYGB). Dietary glucose drives GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) secretion postoperatively. Understanding how glucose triggers incretin secretion following RYGB could lead to new treatments of diabetes and obesity. In vitro, incretin release depends on glucose absorption via sodium-glucose cotransporter 1 (SGLT1). We investigated the importance of SGLT1/SGLT2 for enteropancreatic hormone concentrations and glucose metabolism after RYGB in a randomized, controlled, crossover study. Ten RYGB-operated patients ingested 50 g of oral glucose with and without acute pretreatment with 600 mg of the SGLT1/SGLT2-inhibitor canagliflozin. Paracetamol and 3- O-methyl-d-glucopyranose (3-OMG) were added to the glucose drink to evaluate rates of intestinal entry and absorption of glucose, respectively. Blood samples were collected for 4 h. The primary outcome was 4-h plasma GLP-1 (incremental area-under the curve, iAUC). Secondary outcomes included glucose, GIP, insulin, and glucagon. Canagliflozin delayed glucose absorption (time-to-peak 3-OMG: 50 vs. 132 min, P < 0.01) but did not reduce iAUC GLP-1 (6,067 vs. 7,273·min·pmol -1·L -1, P = 0.23), although peak GLP-1 concentrations were lowered (-28%, P = 0.03). Canagliflozin reduced GIP (iAUC -28%, P = 0.01; peak concentrations -57%, P < 0.01), insulin, and glucose excursions, whereas plasma glucagon (AUC 3,216 vs. 4,160 min·pmol·L -1, P = 0.02) and amino acids were increased. In conclusion, acute SGLT1/SGLT2-inhibition during glucose ingestion did not reduce 4-h plasma GLP-1 responses in RYGB-patients but attenuated the early rise in GLP-1, GIP, and insulin, whereas late glucagon concentrations were increased. The results suggest that SGLT1-mediated glucose absorption contributes to incretin hormone secretion after RYGB.

Original languageEnglish
JournalAmerican Journal of Physiology: Endocrinology and Metabolism
Volume318
Issue number6
Pages (from-to)E956-E964
ISSN0193-1849
DOIs
Publication statusPublished - 1 Jun 2020

    Research areas

  • glucagon, incretins, obesity, Roux-en-Y gastric bypass, sodium-glucose cotransporter

ID: 59613750